AU2022900578A0 - Treatment of clear cell renal carcinoma - Google Patents

Treatment of clear cell renal carcinoma

Info

Publication number
AU2022900578A0
AU2022900578A0 AU2022900578A AU2022900578A AU2022900578A0 AU 2022900578 A0 AU2022900578 A0 AU 2022900578A0 AU 2022900578 A AU2022900578 A AU 2022900578A AU 2022900578 A AU2022900578 A AU 2022900578A AU 2022900578 A0 AU2022900578 A0 AU 2022900578A0
Authority
AU
Australia
Prior art keywords
treatment
clear cell
renal carcinoma
cell renal
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022900578A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Race Oncology Ltd
Original Assignee
Race Oncology Ltd
Filing date
Publication date
Application filed by Race Oncology Ltd filed Critical Race Oncology Ltd
Publication of AU2022900578A0 publication Critical patent/AU2022900578A0/en
Priority to PCT/AU2023/050163 priority Critical patent/WO2023168491A1/en
Pending legal-status Critical Current

Links

AU2022900578A 2022-03-09 2022-03-09 Treatment of clear cell renal carcinoma Pending AU2022900578A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2023/050163 WO2023168491A1 (en) 2022-03-09 2023-03-09 Treatment of clear cell renal cell carcinoma

Publications (1)

Publication Number Publication Date
AU2022900578A0 true AU2022900578A0 (en) 2022-03-24

Family

ID=

Similar Documents

Publication Publication Date Title
EP3990161A4 (en) Reactive electrochemical membrane for wastewater treatment
EP3939610A4 (en) Combined pharmaceutical composition for treating small cell lung cancer
EP3973964A4 (en) Quinoline derivative used for combination treatment of small cell lung cancer
AU2022900578A0 (en) Treatment of clear cell renal carcinoma
EP4054602A4 (en) Epha3 directed car-t cells for treatment of tumors
EP3949966A4 (en) Chiauranib for treatment of small cell lung cancer
AU2022231043A1 (en) Chaperonin-containing tcp-1 inhibitors for the treatment of cancer
AU2020904411A0 (en) Use of bisantrene to treat clear cell renal cell carcinoma
EP3987783A4 (en) Separate constrained directional enhancement filter
EP3965750A4 (en) Cancer stratification and treatment based on inhibition of nod-2
EP3955911A4 (en) Compositions and methods for inhibiting blood cancer cell growth
AU2020904414A0 (en) Use of bisantrene to treat clear cell renal cell carcinoma with mtor
AU2020904417A0 (en) Use of bisantrene to treat clear cell renal cell carcinoma with gf
AU2023903394A0 (en) Water treatment
AU2022903034A0 (en) Cell therapy
GB202308906D0 (en) Treatment of trbc1-positive T cell malignancies
AU2022368937A1 (en) Immunotherapies for the treatment of cancer
TWI843453B (en) Filter
TWI842299B (en) Water treatment system
AU2022903198A0 (en) Methods for treating small cell lung cancer
AU2021901789A0 (en) In-line electrochemical reactor
AU2022902522A0 (en) Treating Myopia
AU2022902521A0 (en) Treating Myopia
AU2020904413A0 (en) Use of bisantrene to treat clear cell renal cell carcinoma with interleukin
AU2022900124A0 (en) Treating COVID